Efficacy and safety of ceftazidime-avibactam in carbapenem-resistant gram-negative bacilli sepsis according to infection site.

ICU and total hospital stays were significantly shorter in the observation group (both P < 0.01).

Subgroup analyses showed favorable outcomes for both pulmonary and urinary tract infections, with the urinary tract subgroup achieving 84.62% clinical efficacy.

Ceftazidime-avibactam treatment was independently associated with microbial clearance (OR=3.74, 95% CI: 1.69-8.27, P=0.001).

No significant difference in adverse events was observed between groups.